OpenSAFELY
Reports

Vaccine Coverage

Description
Montly* report on COVID-19 vaccination coverage in England, based on the population of 23.4m people registered with practices that use TPP SystmOne software. * updates may occasionally be subject to delay.
Contact
Get in touch and tell us how you use this report or new features you'd like to see: [email protected]
First published
22 Dec 2020
Last released
03 May 2022
Links

OpenSAFELY COVID Vaccine coverage report

OpenSAFELY is a new secure analytics platform for electronic patient records built on behalf of NHS England to deliver urgent academic and operational research during the pandemic.

This is our regular weekly report on COVID-19 vaccination coverage in England using data from 40% of general practices that use TPP electronic health record software. The data requires careful interpretation and there are a number of caveats. Please read the full detail about our methods and discussion of our earlier results (as of 17 March 2021) in our peer-reviewed publication in the British Journal of General Practice.

The full analytical methods behind the latest results in this report are available here.

Update: Our vaccine reports are currently published monthly. If you rely on more regular data updates for your own reporting or analysis please contact [email protected] to let us know.

Report last updated 27 Apr 2022

Vaccinations included up to 20 Apr 2022 inclusive

Contents:

Overview of Vaccination Figures to date

Group definitions

  • As of 29 Nov 2021, patient age is calculated at 31 Aug 2021 (previously 31 March 2021), in line with national reporting.
  • The care home group is defined based on patients (aged 65+) having one of these codes.
  • The shielding group is defined based on patients (aged 16-69) having one of these codes provided it was not superceded by one of these codes.
  • The LD (learning disability) group is defined based on patients (aged 16-64) having one of these codes and excludes people who are shielding.
  • Patients are counted in their highest risk category only; e.g. a 65-year-old who is shielding is only counted in the shielding group, not in the 65-69 group.
  • The housebound group is defined based on this codelist and excludes people who were later recorded as not housebound or in a care home. ####
first dose as at 20 Apr 2022 second dose as at 20 Apr 2022 third dose as at 20 Apr 2022
Group
Total vaccinated in TPP 16,861,082 16,142,882 13,102,572
80+ 96.9% (1,023,176 of 1,055,649) 96.2% (1,015,224 of 1,055,649) 93.4% (985,579 of 1,055,649)
70-79 96.4% (2,011,842 of 2,087,960) 95.5% (1,995,007 of 2,087,960) 92.7% (1,936,032 of 2,087,960)
care home 96.4% (108,353 of 112,371) 93.5% (105,014 of 112,371) 87.4% (98,245 of 112,371)
shielding (aged 16-69) 92.2% (755,958 of 819,854) 89.9% (736,911 of 819,854) 77.0% (631,239 of 819,854)
65-69 94.0% (1,025,689 of 1,091,279) 92.8% (1,012,648 of 1,091,279) 88.5% (966,259 of 1,091,279)
LD (aged 16-64) 88.7% (76,391 of 86,079) 85.0% (73,150 of 86,079) 70.4% (60,557 of 86,079)
60-64 92.5% (1,212,680 of 1,311,590) 91.0% (1,194,081 of 1,311,590) 84.8% (1,112,727 of 1,311,590)
55-59 90.6% (1,399,671 of 1,544,088) 89.0% (1,374,464 of 1,544,088) 80.7% (1,246,350 of 1,544,088)
50-54 88.5% (1,405,278 of 1,588,734) 86.5% (1,374,303 of 1,588,734) 75.8% (1,204,203 of 1,588,734)
40-49 81.5% (2,448,726 of 3,005,037) 78.7% (2,363,550 of 3,005,037) 62.7% (1,884,435 of 3,005,037)
30-39 72.7% (2,478,875 of 3,410,428) 68.1% (2,323,363 of 3,410,428) 46.2% (1,574,307 of 3,410,428)
18-29 71.4% (2,535,141 of 3,548,622) 64.2% (2,278,703 of 3,548,622) 37.0% (1,314,355 of 3,548,622)
16-17 70.4% (379,302 of 538,566) 55.1% (296,485 of 538,566) 16.4% (88,277 of 538,566)

NB Patient counts are rounded to nearest 7

Second doses are at least 19 days after the first; third doses at least 8 weeks after the second;

All second and third/booster doses given in these timescales are counted whether or not they were 'due' according to the relevant dosing schedule at the time.

Vaccine types

Note: numbers may not sum to 100% as it is not always possible to determine vaccine type given, and patients occasionally have more than one brand recorded on the same day.

Oxford-AZ vaccines (% of all first doses): 49.7% (8,378,419)

Pfizer vaccines (% of all first doses): 47.4% (7,990,997)

Moderna vaccines (% of all first doses): 2.9% (486,941)

Second doses and dose combinations

Note: second dose figures are raw proportions and do not take into account how many are due, which is likely to vary substantially by brand.
For more detailed analysis please refer to our second dose report

Second doses (% of all vaccinated): 95.7% (16,142,882)

Second doses (% of Ox-AZ first doses): 98.8% (8,282,029)

Second doses (% of Pfizer first doses): 93.3% (7,455,903)

Second doses (% of Moderna first doses): 82.6% (402,157)


Note: mixed doses counts patients with first and second doses at least 19 days apart, excluding patients with two different brands recorded on the same day or recorded on a date prior to when the given brand was available in the UK

Mixed doses Ox-AZ + Pfizer (% of fully vaccinated): 0.6% (98070)

Mixed doses Ox-AZ + Moderna (% of fully vaccinated): 0.1% (15330)

Mixed doses Moderna + Pfizer (% of fully vaccinated): 0.2% (33628)

Summary Charts

Note: 'Priority groups' only includes those identified as being in a priority group by our methodology. 'Others' includes everyone aged 18-49 except those who are shielding or have a learning disability.

*Latest overall cohort rate calculated as at latest date for vaccinations recorded across all TPP practices.

80+ population

COVID vaccinations among 80+ population

by Sex

COVID vaccinations among 80+ population

by Ethnicity (broad categories)

COVID vaccinations among 80+ population

by Index of Multiple Deprivation (quintiles)

COVID vaccinations among 80+ population

by BMI

COVID vaccinations among 80+ population

by Housebound